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PROGNOSTIC FACTORS 
OBTAINED BY A 
PATHOLOGIC EXAMINATION 
IN COMPLETELY RESECTED 
NON-SMALL-CELL LUNG 
CANCER 
An analysis in each 
pathologic stage 
We attempted to clarify what factors predominantly influence the survival 
of patients with non-small-cell lung cancer in each pathologic stage on the 
basis of information generally obtained by a pathologic examination of 
completely resected non-small-cell lung cancer. The subjects included 243 
patients with stage I, 63 with stage II, and 108 with stage IIIA disease. 
Pathologic features used in the analysis were as follows: the greatest tumor 
size (<3.0 cm versus >3.0 cm), the histologic ell type (squamous versus 
nonsquamous cell carcinoma), the grade of differentiation, and tumor 
invasion of pleura and vessels. In stage IIIA, the extent of the metastasis to
the lymph nodes was also included in the analysis. The significant 
prognostic factors (p < 0.05) in stage I demonstrated by a univariate 
analysis of the survival curves included the tumor size, the grade of 
differentiation (weil differentiated versus moderately and poorly differen- 
tiated tumor), pleural involvement, and invasion of the artery and vein. In 
addition, the histologic ell type and the pleural involvement in stage II and 
invasion of the vein and the extent of metastasis to the lymph nodes (NO 
and N1 versus N2) in stage IIIA were also found to be significant prognostic 
factors. A multivariate prognostic factor analysis howed that the grade of 
differentiation, pleural involvement, and venous invasion in stage I; the 
histologic ell type and pleural involvement in stage II; and venous invasion 
and mediastinal lymph node metastasis n stage IIIA were all predominant 
prognostic factors. These observations therefore suggest that a pathologic 
examination can identify the patients with a poor prognosis, which is 
different among the stages. (J THORAC CARDIOVASC SURG 1995;110:601-5) 
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T he survival of patients with non-small-cell ung cancer who undergo a complete resection is 
known to be closely correlated to the pathologic 
stage of the disease. 1 Many studies of resected 
specimens have been recently performed to deter- 
mine the prognostic factors other than the patho- 
logic stage for these patients. For example, an 
abnormal expression of p53 protein, a mutation of 
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the ras gene, or aneuploidy by a deoxyribonucleic 
acid flow cytometry analysis have all been reported 
to be related to a poor prognosis. 2-s On the whole, 
however, no prognostic factor that has a greater 
impact on the survival than the pathologic stage has 
yet been identified. 
An ordinary pathologic examination also provides 
important information on survival. 6-13 So far, the 
grade of differentiation of the tumor and the pres- 
ence of either pleural involvement or vessel invasion 
have been reported to be prognostic factors. To our 
knowledge, however, it still remains unclear as to 
which pathologic feature has a predominant impact 
on the survival in each pathologic stage. Therefore, 
in the present study we attempted to clarify this 
issue. 
Patients and methods 
In the period between April 1972 and December 1988, 
485 patients who had undergone a complete surgical 
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Fig. 1. Survival curves in stage I through IIIA disease. Survival curve between stage I (thin line, n = 243) 
and stage II (medium line, n = 63) or stage III (thick line, n = 108) shows statistically significant difference 
by means of log-rank test (p = 0.000). Difference between stages II and III is marginal (p = 0.077). Bars 
indicate 95% confidence intervals. 
resection of non-small-cell lung cancer were found to have 
pathologic stage I, II, or l i la  disease on the basis of the 
classification of the new international staging system. 1 All 
patients underwent mediastinal node dissection. Out of 
these 485 patients, all the pathologic features described in 
this section were noted in 414 patients. The subjects 
consisted of 243 patients with stage I, 63 with stage II, and 
108 with stage IIIA disease. 
The histopathologic features were analyzed for tumor 
typing and the grade of differentiation, classified accord- 
ing to the World Health Organization, 14and examined for 
pleural and vascular invasion of the tumor. Sections of the 
tumor were stained with hematoxylin and eosin, alcian 
blue, and periodic acid-Schiff stains. Staining of the elastic 
and connective tissue was done when necessary. Vascular 
invasion was determined by identification of the tumor 
cells in the lumen of the endothelium-lined channel. The 
classification of pleural involvement according to the 
Japan Lung Cancer Society is as followsaS: pO, tumor 
having no pleural involvement or reaching the visceral 
pleura but not extending beyond its elastic layer; pl, 
tumor extending beyond the elastic layer of the visceral 
pleural but not exposed on the pleural surface; p2, tumor 
exposed on the pleural surface but not involving the 
parietal pleura; p3, tumor extending to the parietal pleura. 
In the present study, because the number of patients with 
pl or p2 tumors was relatively small and it was sometimes 
difficult to distinguish pl from p2 tumors, pl and p2 
tumors were combined and analyzed as merely an invasion 
of the visceral pleura. 
The minimum follow-up period was 5 years. The sur- 
vival curves of the patients were drawn by means of the 
Kaplan-Meier method, and the statistical evaluation of 
the curves was done by means of the log-tank test. The 
parameters for the determination of a predominant im- 
pact on survival were evaluated by Cox's multivariate 
regression models. 16 The data were considered significant 
when the p value did not exceed 0.05. 
Resu l ts  
Survival in each stage. Fig. 1 shows the survival 
curves of stages I through IIIA. The 5-year survival 
was 75% in stage I, 49% in stage II, and 34% in 
stage IIIA. The survival between stages I and I I  or 
I I IA  demonstrated a statistically significant differ- 
ence. 
Stage I. The survival and statistical evaluation of 
related factors by means of the log-tank test in 
patients with stage I disease are shown in Table I. Of 
the seven factors, tumor size, grade of differentia- 
tion, pleural involvement, and invasion of the artery 
and vein were considered to be significant prognos- 
tic factors by a univariate analysis of the survival 
curves (Table I). In addition, invasion of lymphatic 
vessels tended to have an impact on the survival 
(.p = 0.09). 
Multivariate analyses were done to determine 
which of these six factors had a predominant impact 
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Table I. Survival classified according to the 
histopathologic factors in stage I (n = 243) 
Survival (%) 
Prognostic factor No. 2 yr 3 yr 5 yr X 2 p Value 
Tumor size 
-----3.0 cm 
>_-3.1 cm 
Histologic lassifica- 
tion 
Squamous 
Nonsquamous 
Differentiation 
Well differentiated 
Moderate and 
poor 
Pleural involvernent 
pO 
pl,2 
Invasion of artery 
+ 
Invasion of vein 
+ 
Invasion of lymphatic 
vessel 
+ 
119 92.3 89.7 84.4 6.2882 0.0132" 
124 86.8 75.7 66.0 
87 91.8 83.5 77.1 0.0682 0.7952 
156 88.2 82.1 74.0 
59 98.3 96.6 87.4 9.4157 0.0029* 
184 86.6 78.1 71.1 
159 91.8 85.2 89.9 8.9329 0.0036* 
84 85.0 77.4 65.7 
210 91.2 85.2 78.0 4.2816 0.0407* 
33 78.8 66.7 57.4 
216 91.9 85.6 78.6 13.0908 0.0005* 
27 70.4 59.3 48.1 
116 96.5 89.4 80.3 2.9252 0.0903 
127 83.0 76.4 70.3 
*p < 0.05, considered statistically significant. 
Table III. Survival classified according to the 
histopathologic factors in stage 11 disease (n = 63) 
Survival (%) 
Prognostic factor No. 2 yr 3 yr 5 yr X 2 p Value 
Tumor size 
<3.0 cm 16 87.5 81.3 50.0 0.5423 0.4655 
_>-3.1 cm 47 68.1 55.3 48.9 
Histologic lassifica- 
tion 
Squamous 27 77.8 70.4 63.0 5.7377 0.0184" 
Nonsquamous 36 69.4 55.6 38.7 
Differentiation 
Welldifferentiated 9 88.9 77.8 55.61 0.0255 0.3957 
Moderate 34 70.6 61.8 44.1[ r [ I 
Poor 20 70.0 55.0 55.0] .7236 0.8800 
Pleural involvement 
pO 43 81.4 67.4 55.8 6.6236 0.0101" 
pl,2 20 55.0 50.0 35.0 
Invasion of artery 
- 51 74.5 64.7 48.9 0.1868 0.6694 
+ 12 66.7 50.0 50.0 
Invasion of vein 
- 46 76.1 65.2 49.9 0.0610 0.8066 
+ 17 64.7 52.9 47.1 
Invasion of lymphatic 
vessel 
- 13 76.9 53.8 46.2 0,0010 0.9748 
+ 50 72.0 64.0 49.9 
*p < 0.05, considered statistically significant. 
Table II. A multivariate prognostic factor analysis 
in stage I disease 
Hazard 
Factors ratio 95% CI p Value 
Tumor size 
-<_3.0 cm vs >-_3.1 cm 1.4319 0.8822-2.3241 0.1463 
Differentiation 
Weil vs moderately 2 .2150 1.1131-2.4834 0.0235* 
and po0rly differ- 
entiated 
Pleural invo!vement 
pO vs pl,2 1.8463 1.1557-2.9495 0.0103" 
Invasion of artery 
Absence Vs presence 1 .2153 0.6703-2.2036 0.5207 
Invasion of Vei•t 
Absence Vs presence 2 .1592 1.1846-3.9355 0.0120" 
/ 
Invasion of !ymphatic 
vessel 
Absence Vs presence 1 .2670 0.7825-2.0515 0.3358 
CI, c°nfidence intervat. 
*p < 0.05, coiasidered a predominant prognostic factor. 1 
on survival. As shown in Table II, the grade of 
differentiation (well versus moderately and poorly), 
visceral pleural involvement, and invasion of the 
veins were found to be predominant prognostic 
Table IV. A multivariate prognostic factor analysis 
in stage H disease 
Hazard 
Factors ratio 95% CI p Valne 
Histologic lassification 
Squamous vs 2.0415 1.0118-4.1194 0.0463* 
nonsquamous 
Pleural involvement 
pO vs pl,2 2.0107 1.0470-3.8613 0.0359* 
C/, Confidence interval. 
*p < 0.05, considered a predominant prognostic factor. 
factors. The 5-year survival was 87% in 41 patients 
with well-differentiated pO tumor and 60% in 66 
patients with either a moderately or poorly differ- 
entiated pl,2 tumor. 
Stage II. As shown in Table III, the histologic 
classification and pleural involvement were consid- 
ered to be significant prognostic factors by a univa- 
riate analysis of the survival curves. A multivariate 
analysis also revealed both the histologic classifica- 
tion and pleural involvement o be predominant 
prognostic factors (Table IV). The 5-year survival 
was 71% in 21 patients with pO squamous cell 
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Table V. Survival classified according to the 
histopathologic factors in stage li la disease 
(n = 108) 
Survival (%) 
Prognostic factor No. 2 yr 3 yr 5 yr X e p Value 
Tumor size 
=<3.0 cm 
=>3.1 cm 
Histologic classifica- 
tion 
Squamous 
Nonsquamous 
Differentiation 
Well differentiated 
Moderate 
Poor 
Pleural involvement 
pO 
pl,2 
p3 
Invasion of artery 
+ 
Invasion of vein 
+ 
Invasion of lymphatic 
vessel 
+ 
N factor 
N0,1 
N2 
30 73.3 59.6 38.6 
78 56.6 39.5 31.6 
1.0504 0.3064 
48 68.1 55.2 44.1 1.8704 0.1785 
60 56.0 37.3 25.3 
14 71.4 56.3 40.210.0184 0.6258 
59 64.4 47.5 32.2~ I [ 
35 51.7 36.5 33.510.2422 0.8946 
49 63.3 42.6 27.511.0.1261 0.2666 
27 55.6 44.4 33.3 ~ [ 
32 63.4 50.1 43.4J1.2 35 0.7261 
87 61.6 47.5 34.5 0.0010 0.9748 
21 60.0 35.0 30.0 
83 67.9 51.7 36.6 4.8751 0.0281" 
25 40.0 24.0 24.0 
38 62.2 51.4 43.1 1.5343 0.2190 
70 60.9 41.8 28.4 
29 72.4 69.0 62.1 7.5791 0.0062* 
79 57.2 36.1 22.7 
*p < 0.05, considered statistically significant. 
carcinoma and 36% in 14 patients with pl,2 
nonsquamous cell carcinoma. 
Stage IIIA. The category of stage IIIA is deter- 
mined by the presence of invasion of the parietal 
pleura (p3), metastasis to the mediastinal lymph 
nodes (N2), or a tumor in the main bronchus within 
2 cm of the carina. Only a few patients had the latter 
tumor in our experience. Therefore p3 tumor and 
the extent of metastasis to the lymph nodes (N 
factor) were added to the analysis as shown in Table 
V. Because the number of patients with N1 disease 
was as small as five, both N0 and N1 diseases were 
classified as one group. Of the eight factors, N factor 
and invasion of the vein were considered to be 
significant prognostic factors on the basis of a 
univariate analysis. A multivariate analysis also re- 
vealed venous invasion and N factor to be predom- 
inant prognostic factors (Table VI). The 5-year 
survival was 65% in the 23 patients who had an N0,1 
tumor without venous invasion, and it was 16% in 
Table VI. A multivariate prognostic factor analysis 
in stage lIIA disease 
Hazard 
Factors ratio 95% CI p Value 
Invasion of vein 
Absence vs presence 1.7751 1.0521-2.9949 0.0315" 
N factor 
N0,1 vs N2 2.1586 1.2368-3.7677 0.0068* 
C/, Confidence interval. 
*p < 0.05, considered a predominant prognostic factor. 
the 19 patients with an N2 tumor accompanying 
venous invasion. 
Discussion 
The most important prognostic factors in resected 
non-small-cell ung cancer are known to be the 
pathologic stage of the disease, which is mainly 
based on tumor size and lymph node metastases. 1 
Other morphologic features uch as histologic type, 
degree of differentiation, and vascular or pleural 
invasion, which are ascertained by an ordinary 
pathologic examination of the resected samples, 
have also been reported to be prognostic factors. 6-13 
To our knowledge, however, few studies on these 
pathologic prognostic factors were done after the 
classification of pathologic stage and there are few 
reports on the comparison between pathologic prog- 
nostic factors and each pathologic stage. 
In the present study, visceral pleural involvement 
was found to be a predominant prognostic factor in 
stages I and II by a multivariate prognostic factor 
analysis. Some other reports have made the same 
conclusion on the basis of a univariate analysis) 1'12 
These observations lend support to the current 
definition of T staging in which any tumor with 
visceral pleural invasion is classified as T2 even if the 
greatest dimension of the tumor is only 3 cm or less. 1 
We found that the degree of differentiation is one 
of the predominant prognostic factors in stage I but 
not in stages II and IIIA. The present study shows 
that patients with well-differentiated tumors in stage 
I were significantly more likely to survive than were 
those with moderately or poorly differentiated tu- 
mors. The same observation was found in other 
reports conceming either resected tumors 8' 10, 13 or 
inoperable advanced tumors. 7 Although we did not 
mention recurrent cases in detail, it may be of 
importance to note that the postrecurrent survival in 
patients with well-differentiated tumors in stage I 
was significantly onger than that in those with either 
moderately or poorly differentiated tumors. There- 
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lore, some part of the biologic aggressiveness of
non-small-cell ung cancer may be related to the 
degree of differentiation. In the present study, the 
degree of differentiation was not found to be a 
prognostiC factor in stages II and IIIA and this may 
possibly be because of the small number of patients 
with well-differentiated tumors in these stages. 
Many studies of vascular invasion have concen- 
trated on the veins as a source of blood-borne 
metastases. In fact, venous invasion is found to be a 
predominant prognostic factor in stages I and IIIA. 
Regarding the 88 patients with recurrence in stage I
disease, 22 (25%) and 66 (75%) patients had a local 
and distant recurrent site, respectively. However, 
the first recurrent site in 15 (85%) of 17 patients 
with recurrence whose initial tumor had venous 
invasion was distant (data not shown). 
N2 disease is generally accepted as a significant 
prognostic factor. As shown in the present study, 
even when various histopathologic factors were ex- 
amined t0gether, N2 disease was defined as the most 
important prognostic factor for stage IIIA. The 
5-year survival was 23% in N2 disease and 62% in 
N0,1 disease. Although our 5-year survival in N0,1 
disease seems to be better than that in other re- 
ports, 17 these observations uggest that T3 N0,1 
should be categorized separately from T1 N2 
through T3 N2. 
In conclusion, we found the grade of differentia- 
tion and visceral pleural and venous invasion in 
stage I, visceral pleural invasion and histologic ell 
type in stage II, and venous invasion and mediastinal 
lymph n0de metastasis in stage IIIA all to be 
predominant prognostic factors. Therefore the find- 
ings obtained from an ordinary pathologic examina- 
tion may be useful in the determination of an 
appropriate follow-up schedule or the selection of 
adjuvant herapy trials. 
We express our gratitude to Satoru Inutsuka, MD, of 
Kyushu University for his help with the statistical analysis, 
Brian Quinn for bis critical review, and Yumiko Oshima 
and Yuko Ishibashi for their help in the preparation ofthe 
manuscript. 
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